Literature DB >> 12057912

Fragile histidine triad gene abnormalities in the pathogenesis of gallbladder carcinoma.

Ignacio I Wistuba1, Raheela Ashfaq, Anirban Maitra, Hector Alvarez, Erick Riquelme, Adi F Gazdar.   

Abstract

There is limited information about the molecular changes involved in the pathogenesis of gallbladder carcinoma (GBC). Our recent allelotyping analyses have indicated that chromosome 3p loss of heterozygosity (LOH), including the fragile histidine triad (FHIT) candidate tumor-suppressor gene locus at 3p14.2, is frequently detected in this neoplasm. To investigate the role of the FHIT abnormalities in the multistage sequential development of GBC, 33 formalin-fixed paraffin-embedded invasive GBC specimens and 76 accompanying histologically normal (n = 43) and dysplastic (n = 33) epithelia were examined by immunostaining for expression of Fhit protein. Allele loss at the FHIT gene locus (3p14.2) was studied in all GBCs and in a subset of accompanying gallbladder epithelia by polymerase chain reaction-based LOH analysis, using three 3p14.2 microsatellite markers. In addition, histologically normal epithelium from chronic cholecystitis (n = 19) and dysplasia (n = 13) from gallbladder specimens without cancer were examined for immunostaining and LOH. There was a progressive increase in both the frequency of loss of Fhit expression and LOH at FHIT with increasing severity of histopathological changes. FHIT abnormalities were occasionally demonstrated in histologically normal gallbladder epithelium. Dysplastic foci demonstrated frequent reduction or absence of Fhit immunostaining (38 to 55%) and FHIT allelic loss (33 to 46%). In invasive tumors, these abnormalities were even higher, with 79% reduction or absence of Fhit immunostaining and 76% FHIT allele loss. A high correlation (70%) was observed between Fhit immunostaining abnormalities and allele loss in GBC specimens (P < 0.05). Although a high frequency of FHIT locus breakpoints were detected in both invasive and dysplastic gallbladder specimens, no intronic homozygous deletions on FHIT were detected in GBCs. FHIT gene abnormalities are nearly universal in GBC and these changes are detected early in the sequential development of this neoplasm. Our findings indicate that the FHIT gene is one of the chromosome 3p putative tumor suppressor genes involved in the pathogenesis of this highly malignant neoplasm.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12057912      PMCID: PMC1850840          DOI: 10.1016/S0002-9440(10)61157-1

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  26 in total

1.  Frequent deletions of FHIT and FRA3B in Barrett's metaplasia and esophageal adenocarcinomas.

Authors:  D Michael; D G Beer; C W Wilke; D E Miller; T W Glover
Journal:  Oncogene       Date:  1997-10-02       Impact factor: 9.867

2.  Comparison of molecular changes in lung cancers in HIV-positive and HIV-indeterminate subjects.

Authors:  I I Wistuba; C Behrens; S Milchgrub; A K Virmani; J Jagirdar; B Thomas; H L Ioachim; L A Litzky; E M Brambilla; J D Minna; A F Gazdar
Journal:  JAMA       Date:  1998-05-20       Impact factor: 56.272

3.  The FHIT gene is expressed in pancreatic ductular cells and is altered in pancreatic cancers.

Authors:  C Sorio; A Baron; S Orlandini; G Zamboni; P Pederzoli; K Huebner; A Scarpa
Journal:  Cancer Res       Date:  1999-03-15       Impact factor: 12.701

4.  Abnormal Fhit expression in malignant and premalignant lesions of the cervix.

Authors:  M J Birrer; D Hendricks; J Farley; M J Sundborg; T Bonome; M J Walts; J Geradts
Journal:  Cancer Res       Date:  1999-10-15       Impact factor: 12.701

5.  Role of FHIT in human cancer.

Authors:  C M Croce; G Sozzi; K Huebner
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

6.  Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands.

Authors:  M Ahmadian; I I Wistuba; K M Fong; C Behrens; D R Kodagoda; M H Saboorian; J Shay; G E Tomlinson; J Blum; J D Minna; A F Gazdar
Journal:  Cancer Res       Date:  1997-09-01       Impact factor: 12.701

Review 7.  Genetic abnormalities involved in the pathogenesis of gallbladder carcinoma.

Authors:  I I Wistuba; J Albores-Saavedra
Journal:  J Hepatobiliary Pancreat Surg       Date:  1999

8.  Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma.

Authors:  I I Wistuba; C Behrens; S Milchgrub; D Bryant; J Hung; J D Minna; A F Gazdar
Journal:  Oncogene       Date:  1999-01-21       Impact factor: 9.867

9.  Loss of FHIT function in lung cancer and preinvasive bronchial lesions.

Authors:  G Sozzi; U Pastorino; L Moiraghi; E Tagliabue; F Pezzella; C Ghirelli; S Tornielli; L Sard; K Huebner; M A Pierotti; C M Croce; S Pilotti
Journal:  Cancer Res       Date:  1998-11-15       Impact factor: 12.701

10.  Methylation of the 5' CpG island of the FHIT gene is closely associated with transcriptional inactivation in esophageal squamous cell carcinomas.

Authors:  H Tanaka; Y Shimada; H Harada; M Shinoda; S Hatooka; M Imamura; K Ishizaki
Journal:  Cancer Res       Date:  1998-08-01       Impact factor: 12.701

View more
  17 in total

Review 1.  Common fragile genes and digestive tract cancers.

Authors:  Tamotsu Kuroki; Yoshitsugu Tajima; Jyunichiro Furui; Takashi Kanematsu
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

2.  MSI/LOH and extron expression of the FHIT gene in gastric carcinoma.

Authors:  Yuping Xiao; Lili Mao; Chengbo Han; Jinyi Li; Lei Xu; Yan Xin
Journal:  Front Med China       Date:  2007-02

3.  Loss of heterozygosity and microsatellite instabilities of fragile histidine triad gene in gastric carcinoma.

Authors:  Yu-Ping Xiao; Dong-Ying Wu; Lei Xu; Yan Xin
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

4.  Relationship between abnormality of FHIT gene and EBV infection in gastric cancer.

Authors:  Yu-Ping Xiao; Cheng-Bo Han; Xiao-Yun Mao; Jin-Yi Li; Lei Xu; Chang-Shan Ren; Yan Xin
Journal:  World J Gastroenterol       Date:  2005-06-07       Impact factor: 5.742

5.  Promoter methylation profile in gallbladder cancer.

Authors:  Juan Carlos Roa; Leonardo Anabalón; Iván Roa; Angélica Melo; Juan Carlos Araya; Oscar Tapia; Xavier de Aretxabala; Sergio Muñoz; Barbara Schneider
Journal:  J Gastroenterol       Date:  2006-03       Impact factor: 7.527

6.  Loss of FHIT protein expression correlates with disease progression and poor differentiation in gastric cancer.

Authors:  Alba Rocco; Laslo Schandl; Jie Chen; Hongbing Wang; Zsolt Tulassay; Deirdre McNamara; Peter Malfertheiner; Matthias P A Ebert
Journal:  J Cancer Res Clin Oncol       Date:  2003-03-04       Impact factor: 4.553

7.  Significance of PML and p53 protein as molecular prognostic markers of gallbladder carcinomas.

Authors:  Hee Jin Chang; Byong Chul Yoo; Sun Whe Kim; Byung Lan Lee; Woo Ho Kim
Journal:  Pathol Oncol Res       Date:  2007-12-25       Impact factor: 3.201

Review 8.  [Gallbladder and bile duct carcinoma. Biology and pathology].

Authors:  A Tannapfel; C Wittekind
Journal:  Internist (Berl)       Date:  2004-01       Impact factor: 0.743

Review 9.  Molecular genetics and targeted therapeutics in biliary tract carcinoma.

Authors:  Eric I Marks; Nelson S Yee
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

10.  Two distinct pathways of p16 gene inactivation in gallbladder cancer.

Authors:  Hiroyuki Tadokoro; Takako Shigihara; Tomomi Ikeda; Masaru Takase; Masafumi Suyama
Journal:  World J Gastroenterol       Date:  2007-12-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.